Show simple item record

dc.contributor.authorAughton, K.
dc.contributor.authorElander, N. O.
dc.contributor.authorEvans, A.
dc.contributor.authorJackson, R.
dc.contributor.authorCampbell, F.
dc.contributor.authorCostello, E.
dc.contributor.authorHalloran, C. M.
dc.contributor.authorMackey, J. R.
dc.contributor.authorScarfe, A. G.
dc.contributor.authorValle, Juan W
dc.contributor.authorCarter, R.
dc.contributor.authorCunningham, D.
dc.contributor.authorTebbutt, N. C.
dc.contributor.authorGoldstein, D.
dc.contributor.authorShannon, J.
dc.contributor.authorGlimelius, B.
dc.contributor.authorHackert, T.
dc.contributor.authorCharnley, R. M.
dc.contributor.authorAnthoney, A.
dc.contributor.authorLerch, M. M.
dc.contributor.authorMayerle, J.
dc.contributor.authorPalmer, D. H.
dc.contributor.authorBuchler, M. W.
dc.contributor.authorGhaneh, P.
dc.contributor.authorNeoptolemos, J. P.
dc.contributor.authorGreenhalf, W.
dc.date.accessioned2022-01-11T12:00:10Z
dc.date.available2022-01-11T12:00:10Z
dc.date.issued2021en
dc.identifier.citationAughton K, Elander NO, Evans A, Jackson R, Campbell F, Costello E, et al. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA Vol. 13, Cancers. MDPI AG; 2021. p. 5758.en
dc.identifier.pmid34830914en
dc.identifier.doi10.3390/cancers13225758en
dc.identifier.urihttp://hdl.handle.net/10541/624966
dc.titlehENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNAen
dc.typeArticleen
dc.contributor.departmentLiverpool Experimental Cancer Medicine Centre, 2nd Floor Sherrington Building, Ashton St, University of Liverpool, Liverpool L69 3GE, UKen
dc.identifier.journalCancersen
dc.description.noteen]
refterms.dateFOA2022-04-19T13:12:06Z


Files in this item

Thumbnail
Name:
Hent1.pdf
Size:
1.794Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record